Regeneron Pharmaceuticals Inc. buy Lars
Start price
08.11.21
/
50%
€524.70
Target price
08.11.22
-
Performance (%)
10.50%
End price
21.07.22
€579.80
Summary
This prediction ended on 21.07.22 with a price of €579.80. The BUY prediction by Lars finished with a performance of 10.50%. Lars has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -2.958% | -2.958% | 6.842% | -7.385% |
| iShares Core DAX® | -2.116% | -8.178% | -1.471% | 54.145% |
| iShares Nasdaq 100 | -1.132% | 0.908% | 19.961% | 83.323% |
| iShares Nikkei 225® | -0.658% | -6.257% | 27.473% | 53.605% |
| iShares S&P 500 | -1.261% | -1.001% | 13.631% | 62.624% |
Comments by Lars for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Lars hat das Wertpapier Regeneron Pharmaceuticals Inc. in seinem Wikifolio Wikifolio WF00074737 von Lars gekauft.